Anticancer therapy using glucuronate modified long-circulating liposomes

Area of Science:

• Nanomedicine
• Drug Delivery Systems
• Oncology

Background:

• Conventional liposomes are rapidly cleared by the reticuloendothelial system (RES), limiting their therapeutic applications.
• Targeting non-RES cells with traditional liposomes is challenging due to premature systemic clearance.

Purpose of the Study:

• To develop long-circulating liposomes that evade RES sequestration.
• To enhance passive tumor targeting and improve the efficacy of encapsulated anticancer agents.

Main Methods:

• Modification of liposomes with a glucuronic acid derivative (PGlcUA) and polyethylene glycol (PEG).
• Evaluation of liposome circulation time and RES-trapping avoidance.
• Assessment of passive targeting to tumor tissues via enhanced permeability and retention (EPR) effect.
• Testing the efficacy of PGlcUA-liposome encapsulated drugs (adriamycin, vincristine) in preclinical models.

Main Results:

• PGlcUA-modified liposomes exhibited prolonged circulation times, effectively evading RES uptake.
• These liposomes demonstrated significant accumulation in tumor tissues due to leaky vasculature.
• Encapsulation of adriamycin and vincristine within PGlcUA liposomes resulted in enhanced antitumor efficacy.
• PGlcUA liposomes showed promise in photodynamic therapy and with novel anticancer agents.

Conclusions:

• PGlcUA-modified liposomes represent a promising drug delivery platform for improved cancer therapy.
• Their long-circulating nature and passive tumor targeting capabilities overcome limitations of conventional liposomes.
• These liposomes enhance the efficacy of various anticancer agents and are suitable for tumor imaging and treatment.